Dr Reddy's launches insomnia drug in US; Glenmark gets FDA nod

Pharma major Dr Reddy's Laboratories today said it has launched a drug to treat

RELATED ARTICLES

insomnia in the US market, following approval by the Food & Drug Administration (FDA).

The company has started selling 1 mg, 2 mg and 3 mg tablets of Eszopiclone, a generic version of Lunesta, a sedative drug that is used for the treatment of insomnia.

Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.

According to IMS Health, Lunesta tablets and generics combined had US sales of about $887 million for the 12 months ended January 2014, Dr Reddy's said in a filing with the stock exchanges.

Dr Reddy's said 1 mg tablets are available in bottle counts of 30, while 2 mg and 3 mg tablets will be sold in bottle counts of 100.

Dr Reddy's shares traded at Rs 2,542.95 on the BSE in afternoon trade, down 1.54 per cent.

Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, said in a separate statement that it has been granted final abbreviated new drug approval from the FDA for Eszopiclone tablets.

"Glenmark will commence distribution of the product immediately. The approval is for the 1 mg, 2 mg and 3 mg tablets," Glenmark said in the statement.

Glenmark shares quoted at Rs 582.40 on the BSE, up 0.18 per cent.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Indian-promoted global corporations must follow accounting best practices

    The international advisory board (IAB) of capital market regulator Securities and Exchange Board of India (Sebi) has suggested that separate governanc

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Cost of education must be controlled

In India, we pay very little attention to the cost ...

Rajgopal Nidamboor

Focus to keep your daily qualms at bay

Philosophers and scientists have, for long, compared the human brain ...

Gautam Gupta

What we can learn from the French fashion scene

It was a pleasure and a treat to experience one ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture